Ophthalmology· 2014Q1· Clinical trial

Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema

David S. Boyer, Young Hee Yoon, Rubens Belfort, Francesco Bandello et al.

1,117citations
Q1SCImago
2014year

Short summary

A three-year trial found that dexamethasone intravitreal implants (Ozurdex) at both 0.7 mg and 0.35 mg doses significantly improved visual acuity and reduced retinal thickness in patients with diabetic macular edema compared to sham treatment.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Ophthalmology

OphthalmologyMedicine